The 2024 American Diabetes Association guidelines on Standards of Medical Care in Diabetes: key takeaways for laboratory

Dipti Tiwari , Tar Choon Aw

Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (4) : 158 -66.

PDF (1209KB)
Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (4) :158 -66. DOI: 10.37349/eemd.2024.00013
Commentary
research-article
The 2024 American Diabetes Association guidelines on Standards of Medical Care in Diabetes: key takeaways for laboratory
Author information +
History +
PDF (1209KB)

Abstract

The escalating prevalence of diabetes poses a significant health concern. Uncontrolled diabetes leads to a multitude of complications. A comprehensive management plan and continual adaptation of guidelines is needed. The American Diabetes Association (ADA) is a guiding force in this domain, providing diabetes care recommendations for clinicians, laboratorians, researchers, and policymakers since 1989. The latest ADA guidelines present both challenges and opportunities for laboratories. The increased emphasis on glycated hemoglobin (HbA1c) testing for early diagnosis and personalized monitoring is expected to increase testing volumes, potentially leading to a rise in point-of-care testing. Ensuring standardized testing procedures becomes paramount to maintaining consistent and reliable results across laboratories. Moreover, laboratories may need to expand their test menus to accommodate the growing demand for personalized medicine approaches and collaborate closely with healthcare providers to support informed decision-making. This commentary provides a focused analysis of the 2024 ADA guidelines for the laboratory assessment of diabetes.

Keywords

American Diabetes Association 2024 guidelines / cardiovascular-kidney-metabolic health / continuous glucose monitoring / diabetes / diabetic kidney disease

Cite this article

Download citation ▾
Dipti Tiwari, Tar Choon Aw. The 2024 American Diabetes Association guidelines on Standards of Medical Care in Diabetes: key takeaways for laboratory. Exploration of Endocrine and Metabolic Diseases, 2024, 1 (4) : 158-66 DOI:10.37349/eemd.2024.00013

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

IDF Diabetes Atlas Reports [Internet]. International Diabetes Federation; c2022 [cited 2023 Dec 20]. Available from: https://diabetesatlas.org

[2]

Ortiz-Martínez M, González-González M, Martagón AJ, Hlavinka V, Willson RC, Rito-Palomares M. Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Curr Diab Rep. 2022; 22: 95-115.

[3]

American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S20-42.

[4]

American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S111-25.

[5]

Franceschi R. Precision Medicine in Diabetes, Current Research and Future Perspectives. J Pers Med. 2022; 12: 1233.

[6]

Evans-Molina C, Oram RA. Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol. 2023; 11: 76-7.

[7]

Cherubini V, Chiarelli F. Autoantibody test for type 1 diabetes in children: are there reasons to implement a screening program in the general population? A statement endorsed by the Italian Society for Paediatric Endocrinology and Diabetes (SIEDP-ISPED) and the Italian Society of Paediatrics (SIP). Ital J Pediatr. 2023; 49: 87.

[8]

Burahmah J, Zheng D, Leslie RD. Adult-onset type 1 diabetes: A changing perspective. Eur J Intern Med. 2022; 104: 7-12.

[9]

Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023; 168: 115734.

[10]

Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016; 1: 226-37.

[11]

Shivaswamy V, Boerner B, Larsen J. Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. Endocr Rev. 2016; 37: 37-61.

[12]

Broome DT, Pantalone KM, Kashyap SR, Philipson LH. Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab. 2021; 106: 237-50.

[13]

Kovács G, Nagy D, Szilberhorn L, Zelei T, Gaál Z, Vellekoop H, et al. Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young. Per Med. 2023; 20: 375-85.

[14]

American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S179-218.

[15]

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al.; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023; 388: 1353-64.

[16]

Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2023; 28: 585-96.

[17]

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022; 45: 3075-90.

[18]

Lerma EV. Diagnosis 101: diabetic kidney disease. Clin Kidney J. 2022; 15: 1797-9.

[19]

American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S219-30.

[20]

Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med. 2019; 86: 601-7.

[21]

Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al.; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023; 148: 1606-35.

[22]

American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S145-57.

[23]

Kinnunen J, Nikkinen H, Keikkala E, Mustaniemi S, Gissler M, Laivuori H, et al. Gestational diabetes is associated with the risk of offspring’s congenital anomalies: a register-based cohort study. BMC Pregnancy Childbirth. 2023; 23: 708.

[24]

Zhao D, Liu D, Shi W, Shan L, Yue W, Qu P, et al. Association between Maternal Blood Glucose Levels during Pregnancy and Birth Outcomes: A Birth Cohort Study. Int J Environ Res Public Health. 2023; 20: 2102.

[25]

Yehuda I. Implementation of Preconception Care for Women With Diabetes. Diabetes Spectr. 2016; 29: 105-14.

[26]

American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S282-94.

[27]

Lai M, Weng J, Yang J, Gong Y, Fang F, Li N, et al. Effect of continuous glucose monitoring compared with self-monitoring of blood glucose in gestational diabetes patients with HbA1c<6%: a randomized controlled trial. Front Endocrinol (Lausanne). 2023; 14: 1174239.

[28]

Di Mario C, Genovese S, Lanza GA, Mannucci E, Marenzi G, Sciatti E, et al.; Expert Panel Group. Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus. Cardiovasc Diabetol. 2022; 21: 164.

[29]

American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S126-44.

[30]

Aleppo G, Chmiel R, Zurn A, Bandoske R, Creamer P, Neubauer N, et al. Integration of Continuous Glucose Monitoring Data into an Electronic Health Record System: Single-Center Implementation. J Diabetes Sci Technol. 2023; 19322968231196168.

PDF (1209KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉